转移因子胶囊辅助治疗耐多药肺结核50例疗效分析  

Adjuvant therapeutic effect of transfer factor capsules on 50 patients with multi-drug resistant pulmonary tuberculosis(MDR-PTB)

作　　者：黄必为 黄国楼 李静[1] 

机构地区：[1]惠州市结核病防治研究所,广东惠州516001

出　　处：《中国热带医学》2015年第7期866-868,共3页China Tropical Medicine

摘　　要：目的观察转移因子胶囊对耐多药肺结核辅助治疗的临床疗效。方法采用配对的方法将100例耐多药肺结核患者随机分为化疗+转移因子胶囊组(治疗组)及单纯化疗组(对照组),每组50例。对照组单纯化疗方案主要是吡嗪酰胺、卷曲霉素或卡那霉素、左氧氟沙星或莫西沙星、对氨基水杨酸或环丝氨酸或乙胺丁醇、丙硫异烟肼。治疗组除化疗外还给予转移因子胶囊:6mg,每天3次,共12周。比较两组治疗后3、6、9个月临床疗效。结果治疗3、6、9个月时,治疗组病灶吸收率为72%、78%、84%,均高于对照的48%、54%、58%(P<0.05)。在治疗6和9个月时,治疗组痰菌阴转率为72%和78%,明显高于对照组的52%和54%,差异有统计学意义(P<0.05)。治疗组治疗9个月时空洞闭合率为76%,明显高于对照组的54%,差异有统计学意义(χ2=5.32,P<0.05)。两组均发生发热、皮疹、恶心、肝功能异常等轻微副反应。结论转移因子胶囊联合化学疗法治疗耐多药肺结核可明显提高临床治疗效果。Objective To observe the adjuvant therapeutic effect of transfer factor capsules（TFC） on patients with multi-drug resistant pulmonary tuberculosis（MDR- PTB）.Methods The 100 MDR- PTB patients were randomly divided intotreatment group and the control group. The patients in both groups were all received the same chemotherapy with pyrazinamide,amikacin/capreomycin, kanamycin, levofloxacin/moxifloacin, p-aminosalicylic acid/ cycloserine/ethambutal/C sulfur isoniazid,the patients in treatment group were additionally given TFC 6mg three times a day for 12 weeks.The therapeutic effects onpatients in both groups were compared 3,6 and 9 months after treatment. Results The lesion absorption rates in patients oftreatment group 3,6,9 months after treatment were 72%,78% and 84% respectively, significant higher than 48%,54%,58% inpatients of control group（P〈0.05）.The sputum negative conversion rates in patients of treatment group 6 and 9 months aftertreatment were 72% and 78% respectively,which were significantly higher than 52% and 54% in patients of control group（P〈0.05）. The cavity closure rate in patients of treatment group 9 months after treatment was 76%, significant higher than 54% inpatients of control group（χ^2=5.32,P〈0.05）. Light adverse reactions such as fever, skin rash,nausea and abnormal liver functionwere noticed in patients of both groups. Conclusion Transfer factor capsules in combination with chemotherapy canmarkedly enhance the efficacy in treatment of MDR-PTB patients.

关 键 词：转移因子胶囊 肺结核 耐多药 

分 类 号：R521.1[医药卫生—内科学]